Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England

The first dose of COVID-19 vaccines led to an overall reduction in cardiovascular events, and in rare cases, cardiovascular complications. There is less information about the effect of second and booster doses on cardiovascular diseases. Using longitudinal health records from 45.7 million adults in...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Nature communications Ročník 15; číslo 1; s. 6085 - 12
Hlavní autoři:	Ip, Samantha, North, Teri-Louise, Torabi, Fatemeh, Li, Yangfan, Abbasizanjani, Hoda, Akbari, Ashley, Horne, Elsie, Denholm, Rachel, Keene, Spencer, Denaxas, Spiros, Banerjee, Amitava, Khunti, Kamlesh, Sudlow, Cathie, Whiteley, William N., Sterne, Jonathan A. C., Wood, Angela M., Walker, Venexia
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London Nature Publishing Group UK 31.07.2024 Nature Publishing Group Nature Portfolio
Témata:	2019-nCoV Vaccine mRNA-1273 - administration & dosage 2019-nCoV Vaccine mRNA-1273 - adverse effects 631/326/590 631/326/596/4130 692/699/75 692/700/1538 692/700/478/174 Adolescent Adult Adults Aged Aged, 80 and over BNT162 Vaccine - administration & dosage BNT162 Vaccine - adverse effects Cardiovascular diseases Cardiovascular Diseases - epidemiology Cerebral infarction ChAdOx1 nCoV-19 - administration & dosage ChAdOx1 nCoV-19 - adverse effects Cohort Studies COVID-19 COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - adverse effects Electronic health records Electronic medical records Embolism England - epidemiology Female Heart diseases Humanities and Social Sciences Humans Immunization Immunization, Secondary - adverse effects Incidence Ischemia Male Middle Aged mRNA multidisciplinary Myocardial infarction Myocardial Infarction - epidemiology Myocardial Infarction - etiology Myocarditis Myocarditis - epidemiology Myocarditis - etiology Pericarditis Pulmonary Embolism - epidemiology Pulmonary Embolism - etiology Science Science (multidisciplinary) Thrombocytopenia Thromboembolism Thrombosis Thrombosis - epidemiology Thrombosis - etiology Vaccination - adverse effects Vaccines Young Adult England United Kingdom > UK
ISSN:	2041-1723, 2041-1723
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	The first dose of COVID-19 vaccines led to an overall reduction in cardiovascular events, and in rare cases, cardiovascular complications. There is less information about the effect of second and booster doses on cardiovascular diseases. Using longitudinal health records from 45.7 million adults in England between December 2020 and January 2022, our study compared the incidence of thrombotic and cardiovascular complications up to 26 weeks after first, second and booster doses of brands and combinations of COVID-19 vaccines used during the UK vaccination program with the incidence before or without the corresponding vaccination. The incidence of common arterial thrombotic events (mainly acute myocardial infarction and ischaemic stroke) was generally lower after each vaccine dose, brand and combination. Similarly, the incidence of common venous thrombotic events, (mainly pulmonary embolism and lower limb deep venous thrombosis) was lower after vaccination. There was a higher incidence of previously reported rare harms after vaccination: vaccine-induced thrombotic thrombocytopenia after first ChAdOx1 vaccination, and myocarditis and pericarditis after first, second and transiently after booster mRNA vaccination (BNT-162b2 and mRNA-1273). These findings support the wide uptake of future COVID-19 vaccination programs. COVID-19 vaccines have been associated with rare cardiovascular and thrombotic complications. Here, the authors use population-based longitudinal electronic health record data from ~46 million adults in England to quantify these outcomes following different vaccine doses and schedules.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ISSN:	2041-1723 2041-1723
DOI:	10.1038/s41467-024-49634-x